Summary of test results according to region of origin
| Tests undertaken | Results from completed tests | |||||
| N (% of total) | n (% of N completed tests) | |||||
| Total | Not completed | Completed | Positive | Negative | Indeterminate | |
| T-SPOT.TB | 477 | 57 (12%)* | 420 (88%) | 38 (9%) | 374 (89%) | 8 (2%)† |
| African | 371 | 49 (13%) | 322 (87%) | 30 (9%) | 289 (90%) | 3 (1%) |
| Asian | 106 | 8 (8%) | 98 (93%) | 8 (8%) | 85 (87%) | 5 (5%) |
| QFT-GIT | 460 | 0 (0%) | 460 (100%) | 45 (10%)‡ | 345 (75%) | 70 (15%)§ |
| African | 354 | 0 (0%) | 354 (100%) | 36 (10%) | 251 (71%) | 67 (19%) |
| Asian | 106 | 0 (0%) | 106 (100%) | 9 (8%) | 94 (89%) | 3 (3%) |
| TST | 341 | 37 (11%)¶ | 304 (89%) | 54 (18%) | 250 (82%) | – |
| African | 259 | 34 (13%) | 225 (87%) | 38 (17%) | 187 (83%) | – |
| Asian | 82 | 3 (4%) | 79 (96%) | 16 (20%) | 63 (80%) | – |
↵* 46 (9.6%) insufficient peripheral blood mononuclear cells (PBMCs), 5 (1%) high background, 3 (0.6%) haemolysed, 3 (0.6%) other technical problems.
↵† All failed negative control.
↵‡ 6 (1%) low positive control, but QFT-GIT positive according to manufacturer's directions.
↵§ 66 (14.3%) low positive control, 4 (0.7%) failed negative control.
↵¶ Follow-up reading not obtained.